PURE Bioscience (PURE) 10-K 26 Oct 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jul. 31, 2017	Oct. 26, 2017	Jan. 31, 2017
Document And Entity Information
Entity Registrant Name	PURE BIOSCIENCE, INC.
Entity Central Index Key	1,006,028
Document Type	10-K
Document Period End Date	Jul. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 50,664,000
Entity Common Stock, Shares Outstanding		67,931,861
Trading Symbol	PURE
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Current assets
Cash and cash equivalents	$ 1,640,000	$ 5,194,000
Accounts receivable	297,000	263,000
Inventories, net	273,000	350,000
Restricted cash	75,000	75,000
Prepaid expenses	174,000	260,000
Total current assets	2,459,000	6,142,000
Property, plant and equipment, net	548,000	440,000
Patents, net	822,000	980,000
Total assets	3,829,000	7,562,000
Current liabilities
Accounts payable	426,000	479,000
Restructuring liability	19,000	39,000
Accrued liabilities	230,000	216,000
Derivative liabilities	1,853,000	1,802,000
Total current liabilities	2,528,000	2,536,000
Deferred rent	11,000	3,000
Total liabilities	2,539,000	2,539,000
Commitments and contingencies (See Note 4)
Stockholders' equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 100,000,000 shares authorized, 63,093,153 shares issued and outstanding at July 31, 2017, and 64,823,917 shares issued and outstanding at July 31, 2016	631,000	649,000
Additional paid-in capital	110,141,000	107,593,000
Accumulated deficit	(109,482,000)	(103,219,000)
Total stockholders' equity	1,290,000	5,023,000
Total liabilities and stockholders' equity	$ 3,829,000	$ 7,562,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2017	Jul. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	63,093,153	64,823,917
Common stock, shares outstanding	63,093,153	64,823,917

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income Statement [Abstract]
Net product sales	$ 1,831,000	$ 1,289,000
Operating costs and expenses
Cost of goods sold	760,000	441,000
Selling, general and administrative	5,230,000	5,076,000
Research and development	779,000	927,000
Share-based compensation	1,070,000	1,902,000
Total operating costs and expenses	7,839,000	8,346,000
Loss from operations	(6,008,000)	(7,057,000)
Other income (expense)
Fair value of derivative liabilities in excess of proceeds		(1,867,000)
Change in derivative liabilities	(277,000)	(5,481,000)
Interest expense, net	(5,000)	(10,000)
Other income, net	27,000	44,000
Total other expense	(255,000)	(7,314,000)
Net loss	$ (6,263,000)	$ (14,371,000)
Basic and diluted net loss per share	$ (0.10)	$ (0.25)
Shares used in computing basic and diluted net loss per share	63,492,406	56,830,533

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Jul. 31, 2015	$ 420,000	$ 90,811,000	$ (88,848,000)	$ 2,383,000
Balance, shares at Jul. 31, 2015	41,859,297
Issuance of common stock in private placements, net	$ 177,000	(177,000)
Issuance of common stock in private placements, net, shares	17,777,772
Share-based compensation expense - stock options		358,000		358,000
Share-based compensation expense - restricted stock units		1,544,000		1,544,000
Stock issued for services	$ 3,000	287,000		290,000
Stock issued for services, shares	250,000
Warrant liability removed due to warrant exercise and cancellation		13,550,000		13,550,000
Issuance of common stock upon vesting of restricted stock units	$ 21,000	(21,000)
Issuance of common stock upon vesting of restricted stock units, shares	2,075,000
Issuance of common stock upon exercise of warrants	$ 28,000	1,241,000		1,269,000
Issuance of common stock upon exercise of warrants, shares	2,861,848
Net loss			(14,371,000)	(14,371,000)
Balance at Jul. 31, 2016	$ 649,000	107,593,000	(103,219,000)	5,023,000
Balance, shares at Jul. 31, 2016	64,823,917
Issuance of common stock in private placements, net	$ 16,000	1,033,000		1,049,000
Issuance of common stock in private placements, net, shares	1,572,941
Share-based compensation expense - stock options		968,000		968,000
Share-based compensation expense - restricted stock units		102,000		102,000
Warrant liability removed due to warrant exercise and cancellation		226,000		226,000
Issuance of common stock upon vesting of restricted stock units	$ 1,000	(1,000)
Issuance of common stock upon vesting of restricted stock units, shares	150,000
Issuance of common stock upon exercise of warrants	$ 3,000	182,000		185,000
Issuance of common stock upon exercise of warrants, shares	346,295
Net loss			(6,263,000)	(6,263,000)
Restricted stock unit cancellation	$ (38,000)	38,000
Restricted stock unit cancellation, shares	(3,800,000)
Balance at Jul. 31, 2017	$ 631,000	$ 110,141,000	$ (109,482,000)	$ 1,290,000
Balance, shares at Jul. 31, 2017	63,093,153

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Operating activities
Net loss	$ (6,263,000)	$ (14,371,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	1,070,000	1,902,000
Amortization of stock issued for services	144,000	225,000
Fair value of derivative liabilities in excess of proceeds		1,867,000
Impairment of patents		48,000
Depreciation and amortization	276,000	219,000
Inventory write-off	50,000
Change in fair value of derivative liabilities	277,000	5,481,000
Changes in operating assets and liabilities:
Accounts receivable	(34,000)	(74,000)
Inventories	27,000	(143,000)
Prepaid expenses	(58,000)	(8,000)
Accounts payable and accrued liabilities	(59,000)	(131,000)
Deferred rent	8,000	(6,000)
Net cash used in operating activities	(4,562,000)	(4,991,000)
Investing activities
Investment in patents	(20,000)	(15,000)
Purchases of property, plant and equipment	(206,000)	(390,000)
Net cash used in investing activities	(226,000)	(405,000)
Financing activities
Net proceeds from the sale of common stock	1,049,000	8,000,000
Net proceeds from the exercise of warrants	185,000	1,269,000
Net cash provided by financing activities	1,234,000	9,269,000
Net decrease and increase in cash and cash equivalents	(3,554,000)	3,873,000
Cash and cash equivalents at beginning of year	5,194,000	1,321,000
Cash and cash equivalents at end of year	1,640,000	5,194,000
Supplemental disclosure of cash flow information
Cash paid for taxes	7,000	2,000
Noncash Investing and Financing activities
Warrant liability removed due to settlements	226,000	13,550,000
Restricted stock unit cancelation	38,000
Fair value of warrant liability at issuance		9,867,000
Common stock issued for prepaid services		$ 290,000

Organization and Business

Organization and Business	12 Months Ended
	Jul. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. Organization and Business All references to “PURE,” “we”, “our,” and “us” refer to PURE Bioscience, Inc. and our wholly owned subsidiary. PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent that is manufactured as a liquid delivered in various concentrations. We currently distribute and contract the manufacture and distribution of our SDC-based disinfecting and sanitizing products. We also contract manufacture and sell SDC-based formulations to manufacturers for use as a raw material ingredient in the production of personal care products. We believe our technology platform has potential application in a number of industries. We intend to focus our current resources on providing food safety solutions to the food industry. We were incorporated in the state of California in August 1992 as Innovative Medical Services. In September 2003, we changed our name to PURE Bioscience. In March 2011, we reincorporated in the state of Delaware. We operate in one business segment. Liquidity & Going Concern Uncertainty These consolidated financial statements have been prepared and presented on a basis assuming we will continue as a going concern. The factors below raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Since our inception, we have financed our operations primarily through public and private offerings of securities, debt financing, and revenue from product sales and license agreements. We have a history of recurring losses, and as of July 31, 2017, we have incurred a cumulative net loss of $109,482,000. We do not have, and may never have, significant cash inflows from product sales or from other sources of revenue to fund our operations. As of July 31, 2017, we had $1,640,000 in cash and cash equivalents, and $426,000 of accounts payable. As of July 31, 2017, we had no long-term debt. In October 2017, we completed a tender offer to amend and exercise outstanding warrants held by the investors participating in our 2014, 2015 and 2017 private placement financings, resulting in our receipt of approximately $2.8 million in cash proceeds from the exercise of 4,756,163 outstanding warrants. We do not currently believe that our existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof. Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources. Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether. We do not have any unused credit facilities or other sources of capital available to us at this time. We intend to secure additional working capital through sales of additional debt or equity securities. Our intended financing initiatives are subject to risk, and we cannot provide any assurance about the availability or terms of these or any future financings. If we are unable to obtain sufficient capital, it will have a material adverse effect on our business and operations. It could cause us to fail to execute our business plan, fail to take advantage of future opportunities, or fail to respond to competitive pressures or customer requirements. It also may require us to significantly modify our business model and operations to reduce spending to a sustainable level, which may include delaying, scaling back or eliminating some or all of our ongoing and planned investments in corporate infrastructure, research and development projects, regulatory submissions, business development initiatives, and sales and marketing activities, among other investments. If adequate funds are not available when needed, we may be required to reduce or cease operations altogether. The consolidated financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETIH2O Corporation, a Nevada corporation. ETIH2O Corporation has no business and no material assets or liabilities and there have been no significant transactions related to ETIH2O during the periods presented in the consolidated financial statements. All inter-company balances and transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of three months or less. Restricted Cash The Company is required to maintain $75,000 in a restricted certificate of deposit account in order to fully collateralize four revolving credit card accounts. Fair Value of Financial Instruments Certain of our financial instruments—including cash and cash equivalents, accounts receivable, inventories, prepaid expenses, accounts payable, accrued liabilities, and deferred rent are carried at cost, which is considered to be representative of their respective fair values because of the short-term nature of these instruments. Our derivative liabilities are carried at estimated fair value (See Notes 5 and 6). Derivative Financial Instruments We do not use derivative instruments to hedge exposures to cash flow or market or foreign currency risks. We review the terms of the common stock, warrants and convertible debt we issue to determine whether there are derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including a conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of any convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method. Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates of allowances for doubtful accounts are determined based on historical payment patterns and individual customer circumstances. The allowance for doubtful accounts was zero at July 31, 2017 and 2016. Inventories Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of our property, plant, and equipment range from three to ten years. Capitalized costs associated with leasehold improvements are depreciated over the lesser of the useful life of the asset or the remaining life of the lease. Depreciation is generally included in selling, general and administrative expense. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Patents We have filed a number of patent applications with the United States Patent and Trademark Office and in foreign countries. Certain legal and related costs incurred in connection with pending patent applications have been capitalized. Costs related to successful patent applications are amortized over the lesser of the remaining useful life of the related technology or the remaining patent life, commencing on the date the patent is issued. Capitalized costs related to patent applications are expensed in the period in which a determination is made not to pursue such applications. Impairment of Long-Lived Assets In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. There were no patent impairments during the year ended July 31, 2017. During the year ended July 31, 2016 we incurred $48,000 of expense related to the abandonment of a pending patent not associated with our core business. Revenue Recognition We sell our products to distributors and end users. We record net sales when we sell products to our customers, rather than when our customers resell products to third parties. When we sell products to our customers, we reduce the balance of our inventory with a corresponding charge to cost of goods sold. We do not currently have any consignment sales. Terms of our product sales are generally FOB shipping point. Net sales are recognized when delivery of the products has occurred (which is generally at the time of shipment), title has passed to the customer, the selling price is fixed or determinable, collectability is reasonably assured and we have no further obligations. Any amounts received prior to satisfying these revenue recognition criteria are recorded as deferred revenue. We record sales net of discounts at the time of sale and report sales net of such discounts. We also license our products and technology to development and commercialization partners. Upfront product and technology license fees under multiple-element arrangements are deferred and recognized over the period of such services or performance, if such arrangements require on-going services or performance. Non-refundable amounts received for substantive milestones are recognized upon achievement of the milestone. Any amounts received prior to satisfying these revenue recognition criteria are recorded as deferred revenue. Shipping and Handling Costs Shipping and handling costs incurred by us for product shipments are included in cost of goods sold and were minimal for the years ended July 31, 2017 and 2016. Research and Development Costs Research and development costs are expensed as incurred. Share-Based Compensation We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Other Income (Expense) We record interest income, interest expense, the change in derivative liabilities, as well as other non-operating transactions, as other income (expense) on our consolidated statements of operations. Comprehensive Loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments. For the years ended July 31, 2017 and 2016, our comprehensive loss consisted only of net loss. Income Taxes We recognize deferred tax assets and liabilities for temporary differences between the tax basis of assets and liabilities and the amounts at which they are carried in the financial statements based upon the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established to reduce deferred tax assets to the amount expected to be realized. Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an antidilutive effect. For the years ended July 31, 2017 and 2016, the number of shares issuable upon the exercise of stock options, the vesting of restricted stock units, and the exercise of warrants, none of which are included in the computation of basic net loss per common share, was 16,098,679 and 10,619,394, respectively. Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued a two-part Accounting Standards Update (“ASU”) No. 2017-11, I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception (“ASU 2017-11”). ASU 2017-11 amends guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures. In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15, Presentation of Financial Statements—Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting

Balance Sheet Details

Balance Sheet Details	12 Months Ended
	Jul. 31, 2017
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details	3. Balance Sheet Details Inventories consist of the following: July 31, 2017 2016 Raw materials $ 82,000 $ 120,000 Finished goods 191,000 230,000 $ 273,000 $ 350,000 During the year ended July 31, 2017, we wrote-off $50,000 for slow moving finished goods inventory manufactured in prior years. In addition, during the years ended July 31, 2017 and 2016, we received $34,000 and $46,000, respectively, from the sale of inventory which was reserved in prior fiscal years. The $34,000 and $46,000 gain is reflected in the other income (expense) section of the consolidated statements of operations. Property, plant, and equipment consist of the following: July 31, 2017 2016 Computers and equipment $ 1,045,000 $ 840,000 Furniture and fixtures 21,000 21,000 1,066,000 861,000 Less accumulated depreciation (518,000 ) (421,000 ) $ 548,000 $ 440,000 Depreciation expense was $98,000 and $40,000 for the years ended July 31, 2017 and 2016, respectively. Patents consist of the following: July 31, 2017 2016 Patents $ 3,485,000 $ 3,475,000 Less accumulated amortization (2,663,000 ) (2,495,000 ) $ 822,000 $ 980,000 Patent amortization expense for the years ended July 31, 2017 and 2016 was $178,000 and $179,000, respectively. At July 31, 2017, the weighted average remaining amortization period for all patents was approximately five years. The annual patent amortization expense for the next five years is expected to be approximately $178,000 per year. There were no patent impairments during the year ended July 31, 2017. During the year ended July 31, 2016 we incurred $48,000 of expense related to the abandonment of a pending patent not associated with our core business.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4. Commitments and Contingencies Severance Agreement On August 13, 2013, the Company entered into a Severance and Release Agreement with Dennis Brovarone, a former Board member. Mr. Brovarone will receive $91,000, payable in 60 monthly installments of approximately $1,600, commencing December 11, 2013 for amounts previously accrued as of July 31, 2013. For the years ended July 31, 2017 and 2016, $19,000 and $39,000 remained payable under the agreement and is included in the accrued restructuring liability section of the consolidated balance sheets as of July 31, 2017 and 2016. Operating Leases During August 2016, we amended the lease of our primary facility in El Cajon, California under a noncancelable operating lease that now expires in December 2019. This facility includes our corporate offices, research and development laboratory, and warehouse. Rent expense, including common area maintenance, was $116,000 and $99,000 for the years ended July 31, 2017 and 2016, respectively. Future minimum annual lease payments for our primary facility as of July 31, 2017 are as follows: 2018 $ 94,000 2019 $ 106,000 2020 $ 45,000 $ 245,000

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Jul. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	5 Fair Value of Financial Instruments Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. In connection with the October and November 2015 Private Placements and a prior Bridge Loan, we issued warrants with derivative features. These instruments are accounted for as derivative liabilities (See Note 6). We used Level 3 inputs for the valuation methodology of the derivative liabilities. The estimated fair values were computed using a Monte Carlo option pricing model based on various assumptions. Our derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of the derivative liabilities. Various factors are considered in the pricing models we use to value the warrants, including the Company’s current stock price, the remaining life of the warrants, the volatility of the Company’s stock price, and the risk free interest rate. Future changes in these factors will have a significant impact on the computed fair value of the warrant liability. As such, we expect future changes in the fair value of the warrants to vary significantly from quarter to quarter. The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the years ended July 31, 2017 and 2016: Fair Value of Significant Unobservable Inputs (Level 3) Warrant Liability Balance at July 31, 2015 $ 4,000 Issuances 9,867,000 Settlement of warrant liability (13,550,000 ) Adjustments to estimated fair value 5,481,000 Balance at July 31, 2016 $ 1,802,000 Issuances — Settlement of warrant liability (226,000 ) Adjustments to estimated fair value 277,000 Balance at July 31, 2017 $ 1,853,000

Derivative Liability

Derivative Liability	12 Months Ended
	Jul. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	6. Derivative Liability On October 23, 2015 (the “October Closing Date”), we completed a first closing of a private placement financing (the “2015 Private Placement Financing”), where we issued, among other securities, a warrant to purchase up to an aggregate of 6,666,666 shares of common stock with a term of five years and a warrant to purchase up to an aggregate of 8,666,666 shares of common stock with a term of six months (See Note 7). On November 23, 2015 (the “November Closing Date’), we completed a second and final closing of the 2015 Private Placement Financing, where we issued, among other securities, a warrant to purchase up to an aggregate of 2,222,217 shares of common stock with a term of five years and a warrant to purchase up to an aggregate of 2,820,670 shares of common stock with a term of six months (See Note 7). We accounted for the combined 20,376,219 warrants issued in connection with the 2015 Private Placement Financing in accordance with the accounting guidance for derivatives. The applicable accounting guidance sets forth a two-step model to be applied in determining whether a financial instrument is indexed to an entity’s own stock, which would qualify such financial instruments for a scope exception. This scope exception specifies that a contract that would otherwise meet the definition of a derivative financial instrument would not be considered as such if the contract is both (i) indexed to the entity’s own stock and (ii) classified in the stockholders’ equity section of the entity’s balance sheet. We determined the warrants were ineligible for equity classification due to anti-dilution provisions set forth therein. During the fiscal year ended July 31, 2017, we received approximately $106,000 from the exercise of warrants to purchase 236,116 shares of common stock issued at the November Closing Date. The fair value on the exercise date was returned to additional paid in capital and is reflected in the settlement of warrant liability section on the table above. During the fiscal year ended July 31, 2016, (i) all 2,820,670 of the six-month warrants issued in the second and final closing were exercised, (ii) the six-month warrants issued in the first closing expired and (iii) the five-year warrants issued in the first closing were cancelled. The fair value on the exercise date and the date of expiration and cancelation was returned to additional paid in capital and is reflected in the settlement of warrant liability section on the table above. On the October Closing Date, the derivative liabilities were recorded at an estimated fair value of $7,008,000. Given that the fair value of the derivative liabilities exceeded the total proceeds of the private placement of $6,000,000, no net amounts were allocated to the common stock. The $1,008,000 amount by which the recorded liabilities exceeded the proceeds was charged to other expense at the October Closing Date. On the November Closing Date, the derivative liabilities were recorded at an estimated fair value of $2,859,000. Given that the fair value of the derivative liabilities issued on the November Closing Date exceeded the total proceeds of the private placement of $2,000,000, as of the November Closing Date, no net amounts were allocated to the common stock. The $859,000 amount by which the recorded liabilities exceeded the proceeds was charged to other expense at the November Closing Date. As of July 31, 2017, we had a warrant liability of $1,853,000 related to the 1,986,101 warrants outstanding issued in connection with the November Closing Date of the 2015 Private Placement Financing. The following assumptions were used as inputs to the model at July 31, 2017: stock price of $1.25 per share and a warrant exercise price of $0.45 per share; our historical stock price volatility of 70.00%; risk free interest rate on U.S. treasury notes of 1.6%; warrant expiration of 3.3 years. In addition, as of the valuation date, management assessed the probabilities of future financings assumptions in the valuation model. During the fourth quarter of 2012 we issued 132,420 warrants with derivative features pursuant to a Bridge Loan financing. During the year ended July 31, 2017, of the 9,709 warrants outstanding, there was a net exercise on 5,335 warrants which resulted in the issuance of 4,179 shares of our common stock. As these warrants were net exercised, as permitted under the respective warrant agreement, we did not receive any cash proceeds. The remaining 4,374 warrants issued in connection with the Bridge Loan expired during the year ended July 31, 2017. The fair value on the exercise date and the date of expiration was returned to additional paid in capital and is reflected in the settlement of warrant liability section on the table above. As of July 31, 2017 and 2016, the total value of the derivative liabilities was $1,853,000 and $1,802,000, respectively. The change in fair value of the warrant liability for the year ended July 31, 2017 and 2016, was an increase of $277,000 and $5,481,000, respectively, which was recorded as a change in derivative liability in the consolidated statements of operations. We have revalued the derivative liabilities as of July 31, 2017, and will continue to do so on each subsequent balance sheet date until the securities to which the derivative liabilities relate are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Please see Note 12. Subsequent Events for a discussion of our tender offer to amend and exercise the outstanding warrants held by the investors participating in our 2014, 2015 and 2017 private placement financings.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jul. 31, 2017
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity Preferred Stock As of July 31, 2017, the Company’s Board of Directors is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.01 per share, in one or more series. As of July 31, 2017 and 2016, there were no shares of preferred stock issued and outstanding. Common Stock As of July 31, 2017, 100,000,000 shares of common stock with a par value of $0.01 per share are authorized for issuance. Private Placements On December 1, 2016, we completed an initial closing (the “Initial Closing”) of a private placement financing (the “Private Placement Offering”) to accredited investors. We raised aggregate gross proceeds of $1,000,000 from the sale of (i) an aggregate of 1,176,472 shares of the Company’s common stock at a purchase price of $0.85 per share and (ii) warrants to purchase up to an aggregate of 1,176,472 shares of common stock with a term of five years at an exercise price of $1.25 per share. We determined the warrants issued in connection with the Initial Closing were equity instruments and did not represent derivative instruments. On January 23, 2017, we closed on a second and final closing (the “Final Closing”) of the Private Placement Offering. In the Final Closing we raised aggregate gross proceeds of approximately $337,000 from the sale of (i) an aggregate of 396,469 shares of the Company’s common stock at a purchase price of $0.85 per share and (ii) warrants to purchase up to an aggregate of 396,469 shares of common stock with a term of five years at an exercise price of $1.25 per share. The securities issued in the Private Placement Offering were issued pursuant to a securities purchase agreement entered into with the accredited investors. We determined the warrants issued in connection with the Final Closing were equity instruments and did not represent derivative instruments. We utilized the services of a placement agent for the Private Placement Offering. In connection with the Private Placement Offering, we paid such placement agent an aggregate cash fee of $128,600 and issued to such placement agent or its designees warrants to purchase 151,294 shares of common stock at an exercise price of $1.275 per share. The terms of the placement agent warrants are substantially identical to the investor warrants, other than the exercise price and the holders’ ability to exercise the placement agent warrants on a cashless basis at its discretion. Additionally, we agreed to pay the placement agent a $12,000 due diligence fee and to reimburse the placement agent for fees of counsel up to $35,000. The net proceeds from the Private Placement Offering were approximately $1,049,000 and we are using the net proceeds for general corporate purposes, including our research and development efforts, and for general administrative expenses and working capital. We also entered into a registration rights agreement with the Investors (the “Registration Rights Agreement”), pursuant to which we were obligated to file with the Securities and Exchange Commission (the “SEC”) as soon as practicable, but in any event, by February 6, 2017, on Form S-1 to register 1,572,941 shares of common stock issued to the selling security holders in the Private Placement Offering and up to 1,572,941 shares of our common stock issuable upon the exercise of warrants issued to the selling security holders in the Private Placement Offering. We were obligated to use our commercially reasonable best efforts to cause the registration statement to be declared effective by the SEC within 45 days after the filing of the registration statement (or within 75 days if this registration statement is subject to a full review by the SEC). Additionally, the Registration Rights Agreement provides for certain monetary penalties if the registration statement is not filed or declared effective prior to certain dates, or it is not maintained effective, as set forth in the Registration Rights Agreement. The Private Placement Offering described above was made pursuant to the exemption provided by Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder. On February 6, 2017, we filed a resale registration statement on Form S-1 with the SEC, which was declared effective on February 15, 2017, registering the In the October closing of the 2015 Private Placement Financing we issued 13,333,333 shares of common stock for aggregate gross proceeds to us of $6.0 million. In addition, we issued a warrant to purchase up to an aggregate of 6,666,666 shares of common stock with a term of five years and a warrant to purchase up to an aggregate of 8,666,666 shares of common stock with a term of six months. We did not engage a placement agent or investment banker to facilitate the Private Placement Financing (See Note 6). In the November closing of the 2015 Private Placement Financing we issued 4,444,439 shares of common stock for aggregate gross proceeds to us of $2.0 million. In addition, we issued a warrant to purchase up to an aggregate of 2,222,217 shares of common stock with a term of five years and a warrant to purchase up to an aggregate of 2,820,670 shares of common stock with a term of six months. We did not engage a placement agent or investment banker to facilitate the Private Placement Financing (See Note 6). We offered the securities in the 2015 Private Placement Financing to the Company’s existing investors who previously purchased securities in our private placement financings in August and September of 2014 (the “Prior Financings”). Tom Lee, a member of our board of directors and a participant in the Prior Financings, together with certain of his affiliates, invested approximately $472,000 in the final closing of the 2015 Private Placement Financing on the same terms offered to the other Investors. During the fiscal year ended July 31, 2016, (i) all 2,820,670 of the six-month warrants issued in the second and final closing of the 2015 Private Placement were exercised, (ii) the six-month warrants issued in the first closing of the 2015 Private Placement expired and (iii) the five-year warrants issued in the first closing of the 2015 Private Placement were cancelled. We also entered into a registration rights agreement with the Investors in the 2015 Private Placement Financing (the “Registration Rights Agreement”), pursuant to which we are obligated, upon request of the Investor in the October closing of the 2015 Private Placement Financing and subject to certain conditions, to file with the SEC as soon as practicable, but in any event within 60 days after receiving such applicable request, a registration statement on Form S-1 (the “2015 Resale Registration Statement”) to register the Purchase Shares and the Warrant Shares for resale under the Securities Act of 1933, as amended (the “Securities Act”) and other securities issued or issuable with respect to or in exchange for the Purchase Shares or Warrant Shares. We are obligated to use our commercially reasonable efforts to cause the 2015 Resale Registration Statement to be declared effective by the SEC as promptly as reasonably practicable after the filing of the Resale Registration Statement, but no monetary penalty or liquidated damages will be imposed upon the Company if the Registration Statement is not declared effective by the SEC. Other Activity During the fiscal year ended July 31, 2016, we entered into a two-year service agreement for general financial advisory services. In accordance with the agreement we issued 250,000 shares of common stock, with a value of $290,000. The value was capitalized to prepaid expense and is being amortized over the term of the agreement. For the years ended July 31, 2017 and 2016, we recognized $144,000 and $43,000, respectively, of expense related to these services. In addition, during the year ended July 31, 2016, we recognized $182,000 of expense for services rendered associated with stock issued in prior years. Warrants During the fiscal year ended July 31, 2017, we received approximately $185,000 from the exercise of warrants to purchase 342,116 shares of common stock. 236,116 of the warrants exercised contained derivative features, while 106,000 of the warrants exercised were considered equity instruments. In addition, there was a net exercise on 5,335 warrants which resulted in the issuance of 4,179 shares of our common stock (See Note 6). During the fiscal year ended July 31, 2016, we received $1,269,000 from the exercise of warrants issued in November 2015 to purchase 2,820,670 shares of our common stock. In addition, there was a net exercise on 78,000 warrants which resulted in the issuance of 41,178 shares of our common stock. As these warrants were net exercised, as permitted under the respective warrant agreement, we did not receive any cash proceeds. The warrants were issued in connection with a prior year private placement and were considered equity instruments. A summary of our warrant activity and related data is as follows: Shares Outstanding at July 31, 2015 5,035,156 Issued 20,376,219 Exercised (2,898,670 ) Expired (15,456,279 ) Outstanding at July 31, 2016 7,056,426 Issued 1,724,235 Exercised (347,451 ) Expired/Cancelled (129,374 ) Outstanding at July 31, 2017 8,303,836 The following table summarizes information related to warrants outstanding at July 31, 2017: Expiration Exercise Date Price Shares 09/17/17 $ 1.38 113,520 01/24/18 $ 0.83 375,000 08/29/19 $ 0.75 4,104,980 11/23/20 $ 0.45 1,986,101 12/01/21 $ 1.25 1,176,472 12/01/21 $ 1.28 117,647 01/23/22 $ 1.25 396,469 01/23/22 $ 1.28 33,647 8,303,836 Restricted Stock Units During the fiscal years ended July 31, 2017 and 2016, we issued 150,000 and 2,075,000 shares of common stock to employees and directors for restricted stock units that vested, based on service conditions, respectively (See Note 8).

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	8. Share-Based Compensation Restricted Stock Units During the fiscal year ended July 31, 2017, the Compensation Committee of the Board of Directors authorized the issuance of 1,150,000 Restricted Stock Units (“RSUs”) to our officers and directors. The breakdown is as follows: ● Henry R. Lambert RSU Award: We granted Mr. Lambert an award consisting of two hundred thousand (200,000) RSUs. 25% of the RSUs vest on December 31, 2018 with the remaining shares vesting in three equal annual installments thereafter. ● Chairman RSU Award: We granted Mr. Pfanzelter an award consisting of five hundred thousand (500,000) RSUs. 25% of the RSUs vest on December 31, 2018 with the remaining shares vesting in three equal annual installments thereafter. ● Director RSU Awards: We granted Messrs. Cohee, Lee, and Otis, awards consisting of one hundred fifty thousand (150,000) RSUs, respectively. 50% of the RSUs will vest on the earlier of the date of our annual meeting of stockholders held in 2018 or January 15, 2018 and 50% of the RSUs will vest on the earlier of the date of our annual meeting of stockholders held in 2019 or January 15, 2019. A summary of our restricted stock unit activity and related data is as follows: Shares Outstanding at July 31, 2015 3,210,000 Granted 1,272,500 Vested (2,075,000 ) Forfeited (1,122,500 ) Outstanding at July 31, 2016 1,285,000 Granted 1,150,000 Vested (150,000 ) Forfeited (250,000 ) Outstanding at July 31, 2017 2,035,000 During the fiscal year ended July 31, 2017, 150,000 RSUs vested based on service conditions that were satisfied during the period, resulting in the issuance of 150,000 shares of common stock. Of the 2,035,000 RSUs outstanding, we currently expect 1,150,000 to vest. As of July 31, 2017, there was $1,302,000 of unrecognized non-cash compensation cost related to RSUs we expect to vest, which will be recognized over a weighted average period of 3.32 years. During the fiscal year ended July 31, 2016, 2,075,000 RSUs vested based on service conditions that were satisfied during the period, resulting in the issuance of 2,075,000 shares of common stock. In addition, we granted 1,272,500 RSUs that vest based on service and performance conditions. During the year ended July 31, 2017 and 2016, no RSUs granted in prior years vested based on performance conditions. For the years ended July 31, 2017 and 2016, share-based compensation expense for RSUs was $102,000 and $1,544,000, respectively. RSU Termination On December 13, 2016, we entered into an RSU Cancellation Agreement with our officers and directors who received RSUs in October 2013 as compensation for their continued services to us over a required vesting period. Under this Agreement, our officers and directors agreed to cancel RSUs representing the right to receive an aggregate of 3.9 million vested shares of our common stock. Pursuant to the terms of the cancelled RSUs, we would have been required to settle and deliver these vested shares to the individual officers and directors prior to January 1, 2017, which would have triggered a taxable event. Our officers and directors, in their individual capacities, voluntarily agreed to cancel their respective RSUs based on their determination that cancelling the RSUs would be in the best interests of the Company and our stockholders. The individual officers and directors reached this conclusion for the following reasons: 1. Conserves our Available Cash Resources 2. Reduces Pressure on Our Stock Price Each of our officers and directors who are parties to the RSU Cancellation Agreement agreed to cancel their RSUs and the shares of common stock underlying the RSUs in their individual capacities as stockholders and equity award holders, and without any agreement or promise from us or our officers or directors to issue them equity, equity-based awards or cash compensation in the future in exchange for entering into the Agreement. During the fiscal year ended July 31, 2017, $87,000 of pre-vest expense was reversed as a result of the RSU cancelation. Stock Option Plans In February 2016, we amended and restated our 2007 Equity Incentive Plan, or the Plan, to, among other changes, increase the number of shares of common stock issuable under the Plan by 4,000,000 shares and extend the term of the Plan until February 4, 2026. The Plan During the fiscal year ended July 31, 2017, the Compensation Committee of the Board of Directors authorized the issuance of 2,950,000 stock options to our officers and directors. Each option represents the right to receive one share of common stock, issuable at the time the option vests, as set forth in the option agreement. The breakdown is as follows: ● Henry R. Lambert Option Awards: We granted Mr. Lambert an award consisting of an option to purchase two hundred thousand (200,000) shares of common stock. The option has a five-year term and vests in four quarterly installments. In addition, we granted Mr. Lambert an award consisting of an option to purchase four hundred thousand (400,000) shares of common stock. The option has a ten-year term and vests 25% on December 31, 2018 with the remaining shares vesting in three equal annual installments thereafter. ● Mark S. Elliott Option Award: We granted Mr. Elliott an award consisting of an option to purchase one hundred fifty thousand (150,000) shares of common stock. The option has a five-year term and vests in four quarterly installments. ● Chairman Option Awards: We granted Mr. Pfanzelter an award consisting of an option to purchase two hundred thousand (200,000) shares of common stock. The option has a five-year term and vests in four quarterly installments. In addition, we granted Mr. Pfanzelter an award consisting of an option to purchase one million (1,000,000) shares of common stock. The option has a ten-year term and vests 25% on December 31, 2018 with the remaining shares vesting in three equal annual installments thereafter. ● Director Option Awards: We granted Messrs. Cohee, Lee, Otis and Dr. Theno, awards consisting of an option to purchase one hundred thousand (100,000) shares of common stock, respectively. The option has a five-year term and vests quarterly in four installments. In addition, we granted Messrs. Cohee, Lee and Otis awards consisting of an option to purchase two hundred thousand (200,000) shares of common stock, respectively. The option has a ten-year term with 50% vesting on the earlier of the date of our annual meeting of stockholders held in 2018 or January 15, 2018 and 50% vesting on the earlier of the date of our annual meeting of stockholders held in 2019 or January 15, 2019. During the fiscal year ended July 31, 2016, the Compensation Committee of the Board of Directors authorized the issuance of 950,000 stock options to our officers and directors. Each option represents the right to receive one share of common stock, issuable at the time the option vests, as set forth in the option agreement. The breakdown is as follows: ● We granted Mr. Lambert a five year award consisting of an option to purchase two hundred thousand (200,000) shares of common stock. ● Mark S. Elliott Option Award: We granted Mr. Elliott a two year award consisting of an option to purchase one hundred fifty thousand (150,000) shares of common stock. The option shares vest quarterly over a one year period. ● Chairman Option Award: We granted Mr. Pfanzelter a five year award consisting of an option to purchase two hundred thousand (200,000) shares of common stock. ● Director Option Awards: We granted Messrs. Cohee, Lee, Otis and Dr. Theno, five year awards consisting of an option to purchase one hundred thousand (100,000) shares of common stock, respectively. The option awards granted to Messrs. Lambert, Pfanzelter, Cohee, Lee, Otis and Dr. Theno vested in three installments: 33% on During the years ended July 31, 2017 and 2016, none of the options granted to our officers and directors were granted pursuant to any compensatory, bonus, or similar plan maintained or otherwise sponsored by the Company. During the year ended July 31, 2017, we issued 600,000 options to purchase common stock to employees supporting our selling, general and administrative, and research and development functions and 85,000 options to purchase common stock to third-party consultants for business development and investor relations services. In addition, five-year term and vest in four quarterly installments. During the year ended July 31, 2016, we issued 850,000 options to purchase common stock to employees supporting our selling, general and administrative, and research and development functions. The vesting terms of the options varied from 100% on grant date to quarterly over a one year period. In addition, during the year ended July 31, 2016, we issued 50,000 options to purchase common stock to third-party consultants for business development services. 12,500 option shares vested during the year ended July 31, 2016. The remaining options vest only if sales milestones are achieved. We currently do not expect the remaining options issued under the agreements to vest. A summary of our stock option activity for the fiscal years ended July 31, 2017 and 2016 is as follows: Shares Weighted- Average Exercise Price Aggregate Intrinsic Value Outstanding at July 31, 2015 434,218 $ 4.07 $ — Granted 1,850,000 $ 1.07 Exercised — $ — Cancelled (6,250 ) $ 2.20 Outstanding at July 31, 2016 2,277,968 $ 1.60 $ 46,000 Granted 3,735,000 $ 1.05 Exercised — $ — Cancelled (253,125 ) $ 1.42 Outstanding at July 31, 2017 5,759,843 $ 1.25 $ 1,120,000 The weighted-average remaining contractual term of options outstanding at July 31, 2017 was 5.66 years. At July 31, 2017, options to purchase 2,729,843 shares of common stock were exercisable. These options had a weighted-average exercise price of $1.43, an aggregate intrinsic value of $654,000, and a weighted average remaining contractual term of 3.21 years. The weighted average grant date fair value for options granted during the years ended July 31, 2017 and 2016, was $0.67 and $0.47, respectively. The total unrecognized compensation cost related to unvested stock option grants as of July 31, 2017 was approximately $1,892,000 and the weighted average period over which these grants are expected to vest is 3.05 years. For the fiscal year ended July 31, 2017 and 2016, share-based compensation expense for stock options was $968,000 and $358,000 respectively. We use the Black-Scholes valuation model to calculate the fair value of stock options. Share-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: For the years ended July 31, 2017 2016 Volatility 81.00 % 82.12 % Risk-free interest rate 1.70 % 0.83 % Dividend yield 0.0 % 0.0 % Expected life 4.66 years 2.13 years Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. We have not had significant forfeitures of stock options granted to employees and directors as a significant number of our historical stock option grants were fully vested at issuance or were issued with short vesting provisions. Therefore, we have estimated the forfeiture rate of our outstanding stock options as zero.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jul. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	9. Related Party Transactions On December 11, 2013, the Company entered into a five-year strategic collaboration agreement with St. Louis-based Intercon Chemical Company (ICC). The agreement consists of a multi-prong approach to accelerate the commercialization of PURE’s unique and proprietary SDC-based products. The strategic collaboration agreement provides: ● ICC licenses from PURE its patents and technology know-how for the exclusive manufacture of our SDC-based products. ● ICC will invest in plant improvements to allow for expanded SDC production. ● ICC’s R&D team will collaborate on SDC product line development. ● ICC licenses the distribution rights for SDC-based products into its core businesses of institutional cleaning and sanitation products. ● ICC will also develop a new initiative focused on US hospital, healthcare and medical facilities. ● PURE earns royalty income on SDC-products sold by ICC and its affiliates. During the years ended July 31, 2017 and 2016, our net product sales to ICC was $33,000 and $34,000, respectively. As of July 31, 2017, $75,000 was payable to ICC for the production of SDC based products and $6,000 of accounts receivable was due to the Company. As of July 31, 2016, $118,000 was payable to ICC for the production of SDC based products and $24,000 of accounts receivable was due to the Company. The president of ICC is a shareholder of the Company.

Sales Concentration

Sales Concentration	12 Months Ended
	Jul. 31, 2017
Risks and Uncertainties [Abstract]
Sales Concentration	10. Sales Concentration Net product sales were $1,831,000 and $1,289,000 for the years ended July 31, 2017 and 2016, respectively. For the year ended July 31, 2017, two individual customers accounted for 33% and 19%, of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. The geographic breakdown of net product sales for the year ended July 31, 2017 was as follows: 100% U.S. For the year ended July 31, 2016, one customer accounted for 37% of our net product sales. No other individual customer accounted for 10% or more of our net product sales. The geographic breakdown of net product sales for the year ended July 31, 2016 was as follows: 100% U.S.

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes We file federal and state consolidated tax returns with our subsidiaries. Our income tax provision for the year ended July 31, 2017 and 2016 was $1,600; the minimum state franchise taxes we pay regardless of income or loss. At July 31, 2017, we had federal and state tax net operating loss carry-forwards of approximately $100.3 million and $74.7 million, respectively. Included in these net operating loss carry-forwards is $18.6 million related to a deduction for income tax purposes for which the Company has not realized a tax benefit. In future periods an adjustment would be recorded to Additional Paid in Capital at the time that these net operating losses may be utilized and reduce income tax. At July 31, 2016, we had federal and state tax net operating loss carry-forwards of approximately $95.4 million and $79.0 million, respectively. Utilization of the net operating loss carry-forwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code as well as similar state provisions. These ownership changes may limit the amount of net operating loss carry-forwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 of the Internal Revenue Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since our formation, we have raised capital through the issuance of capital stock on several occasions (both before and after our initial public offering in 1996) which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition. While we do not believe that we have experienced an ownership change, the pertinent tax rules related thereto are complex and subject to varying interpretations, and thus complete assurance cannot be provided that the taxing authorities would not take an alternative position. Our current federal tax loss carry-forwards begin expiring in the year ended July 31, 2019 and, unless previously utilized, will completely expire in the year ending July 31, 2037. Our state tax loss carry-forwards begin to expire in the year ending July 31, 2018, and will completely expire in the year ending July 31, 2037. Significant components of our deferred tax assets are as follows: July 31, 2017 2016 Net operating loss carry-forward $ 30,970,000 $ 30,160,000 Stock options and warrants 3,250,000 3,250,000 Other temporary differences (140,000 ) (140,000 ) Total deferred tax assets 34,080,000 33,270,000 Valuation allowance for deferred tax assets (34,080,000 ) (33,270,000 ) Net deferred tax assets $ — $ — Realization of our deferred tax assets, which relate to operating loss carry-forwards and timing differences, is dependent on future earnings, among other factors. The timing and amount of future earnings are uncertain and therefore a valuation allowance has been established. The increase in the valuation allowance on the deferred tax asset during the years ended July 31, 2017 and 2016 was $810,000 and $2,423,000, respectively. A reconciliation of income taxes computed using the statutory income tax rate, compared to the effective tax rate, is as follows: 2017 2016 Federal tax benefit at the expected statutory rate 34.0 % 34.0 % State income tax, net of federal tax benefit 0.8 1.9 Expired net operating loss carryforwards (6.6 ) (1.5 ) Other (7.7 ) — Change in state tax rates (4.2 ) — Permanent items (3.3 ) (17.9 ) Valuation allowance (13.0 ) (16.5 ) Income tax benefit - effective rate 0.0 % 0.0 % Following authoritative guidance, we recognize the tax benefit from a tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense; however we have had no accrued interest or penalties at either July 31, 2017 or July 31, 2016. We are subject to income taxes in the United States and in various states, and our historical tax years remain subject to future examination by the U.S. and state tax authorities. During the years ended July 31, 2017 and 2016, we did not record any activity related to our unrecognized tax benefits. The Company and its subsidiaries are subject to federal income tax as well as income tax of multiple state jurisdictions. With few exceptions, the Company is no longer subject to income tax examination by tax authorities in major jurisdictions for tax years prior to 2012. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the carryforwards. The Company is not currently under examination by the IRS or state taxing authorities.

Subsequent Events

Subsequent Events	12 Months Ended
	Jul. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On October 10, 2017, we closed a tender offer to amend and exercise outstanding warrants to purchase shares of our Common Stock. Specially, we filed a Schedule TO with the Securities and Exchange Commission (the “SEC”) on August 25, 2017 offering to (i) reduce the exercise price of the warrants to purchase 4,104,980 shares of Common Stock issued to investors participating in our private placement financing completed on August 29, 2014, as amended (the “2014 Warrants”) from $0.75 per share to $0.60 per share of Common Stock in cash, (ii) reduce the exercise price of outstanding warrants to purchase 1,986,101 shares of Common Stock issued to investors participating in our private placement financing completed on November 23, 2015 (the “2015 Warrants”) from $0.45 per share to $0.40 per share of Common Stock in cash, (iii) reduce the exercise price of the outstanding warrants to purchase 1,572,941 shares of Common Stock issued to investors participating in our private placement financing completed on January 23, 2017 (the “2017 Warrants”, together with the 2014 Warrants and 2015 Warrants, the “Original Warrants”) from $1.25 per share to $0.85 per share of Common Stock in cash, (iv) shorten the exercise period of the Original Warrants so that they expired concurrently with the expiration of the Offer to Amend and Exercise at 5:00 p.m. (Pacific Time) on September 25, 2017 (“Expiration Date”) unless extended until the Subsequent Expiration Date (as defined below), (v) delete the cashless exercise provisions in the Original Warrants and (vi) delete the price-based anti-dilution provisions contained in the 2015 Warrants. Additionally, we requested the holders of a majority of the shares issuable upon exercise of the 2014 Warrants (the “2014 Requisite Majority”), 2015 Warrants (the “2015 Requisite Majority”) and 2017 Warrants (the “2017 Requisite Majority”) to approve an amendment of all of the outstanding 2014 Warrants, 2015 Warrants and 2017 Warrants, respectively, to amend such Original Warrants in the same manner as set forth above (the “Aggregate Warrant Amendment”), except the Expiration Date would be extended until October 10, 2017 (the “Subsequent Expiration Date”) if such Aggregate Warrant Amendment was approved with respect to such class of Original Warrants. The 2015 Requisite Majority approved an amendment of all of the outstanding 2015 Warrants and holders of 2015 Warrants had until the Subsequent Expiration Date to exercise their 2015 Warrants (the “Subsequent Offer Period”). The Offer to Amend and Exercise with respect to the 2014 Warrants and 2017 Warrants expired on the Expiration Date of September 25, 2017. As of September 25, 2017, 1,491,649 shares of Common Stock were issued upon exercise of 2014 Warrants, 1,599,135 shares of Common Stock were issued upon exercise of 2015 Warrants and 1,396,470 shares of Common Stock were issued upon exercise of 2017 Warrants, for aggregate gross proceeds to us of approximately $2.72 million. During the Subsequent Offer Period, 2015 Warrants to purchase 268,909 shares of Common Stock were exercised for aggregate gross proceeds to us of approximately $107,000. 2014 Warrants to purchase 2,533,331 shares of Common Stock and 2017 Warrants to purchase 176,471 shares of Common Stock at exercise prices of $0.75 per share and $1.25 per share, respectively, continue to remain outstanding. 2015 Warrants that were not exercised by the Subsequent Expiration Date expired unexercised on such date. Original Warrants (including 2015 Warrants exercised during the Subsequent Offer Period) to purchase an aggregate of 4,756,163 shares of Common Stock were tendered and exercised in the Offer to Amend and Exercise for aggregate gross proceeds to us of approximately $2.83 million. Garden State Securities Inc. assisted the Company as warrant solicitation agents with respect to the 2017 Warrants. Additionally, we previously recorded a warrant liability on our financial statements with respect to the 2015 Warrants due to certain anti-dilution provisions contained in such warrants. Upon the exercise and expiration of the 2015 Warrants, the warrant liability existing on the Company’s consolidated financial statements has been terminated.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETIH2O Corporation, a Nevada corporation. ETIH2O Corporation has no business and no material assets or liabilities and there have been no significant transactions related to ETIH2O during the periods presented in the consolidated financial statements. All inter-company balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of three months or less.
Restricted Cash	Restricted Cash The Company is required to maintain $75,000 in a restricted certificate of deposit account in order to fully collateralize four revolving credit card accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Certain of our financial instruments—including cash and cash equivalents, accounts receivable, inventories, prepaid expenses, accounts payable, accrued liabilities, and deferred rent are carried at cost, which is considered to be representative of their respective fair values because of the short-term nature of these instruments. Our derivative liabilities are carried at estimated fair value (See Notes 5 and 6).
Derivative Financial Instruments	Derivative Financial Instruments We do not use derivative instruments to hedge exposures to cash flow or market or foreign currency risks. We review the terms of the common stock, warrants and convertible debt we issue to determine whether there are derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including a conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of any convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method.
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates of allowances for doubtful accounts are determined based on historical payment patterns and individual customer circumstances. The allowance for doubtful accounts was zero at July 31, 2017 and 2016.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of our property, plant, and equipment range from three to ten years. Capitalized costs associated with leasehold improvements are depreciated over the lesser of the useful life of the asset or the remaining life of the lease. Depreciation is generally included in selling, general and administrative expense. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.
Patents	Patents We have filed a number of patent applications with the United States Patent and Trademark Office and in foreign countries. Certain legal and related costs incurred in connection with pending patent applications have been capitalized. Costs related to successful patent applications are amortized over the lesser of the remaining useful life of the related technology or the remaining patent life, commencing on the date the patent is issued. Capitalized costs related to patent applications are expensed in the period in which a determination is made not to pursue such applications.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. There were no patent impairments during the year ended July 31, 2017. During the year ended July 31, 2016 we incurred $48,000 of expense related to the abandonment of a pending patent not associated with our core business.
Revenue Recognition	Revenue Recognition We sell our products to distributors and end users. We record net sales when we sell products to our customers, rather than when our customers resell products to third parties. When we sell products to our customers, we reduce the balance of our inventory with a corresponding charge to cost of goods sold. We do not currently have any consignment sales. Terms of our product sales are generally FOB shipping point. Net sales are recognized when delivery of the products has occurred (which is generally at the time of shipment), title has passed to the customer, the selling price is fixed or determinable, collectability is reasonably assured and we have no further obligations. Any amounts received prior to satisfying these revenue recognition criteria are recorded as deferred revenue. We record sales net of discounts at the time of sale and report sales net of such discounts. We also license our products and technology to development and commercialization partners. Upfront product and technology license fees under multiple-element arrangements are deferred and recognized over the period of such services or performance, if such arrangements require on-going services or performance. Non-refundable amounts received for substantive milestones are recognized upon achievement of the milestone. Any amounts received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs incurred by us for product shipments are included in cost of goods sold and were minimal for the years ended July 31, 2017 and 2016.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred.
Share-based Compensation	Share-Based Compensation We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures.
Other Income (expense)	Other Income (Expense) We record interest income, interest expense, the change in derivative liabilities, as well as other non-operating transactions, as other income (expense) on our consolidated statements of operations.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments. For the years ended July 31, 2017 and 2016, our comprehensive loss consisted only of net loss.
Income Taxes	Income Taxes We recognize deferred tax assets and liabilities for temporary differences between the tax basis of assets and liabilities and the amounts at which they are carried in the financial statements based upon the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established to reduce deferred tax assets to the amount expected to be realized.
Net Loss Per Share	Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an antidilutive effect. For the years ended July 31, 2017 and 2016, the number of shares issuable upon the exercise of stock options, the vesting of restricted stock units, and the exercise of warrants, none of which are included in the computation of basic net loss per common share, was 16,098,679 and 10,619,394, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued a two-part Accounting Standards Update (“ASU”) No. 2017-11, I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception (“ASU 2017-11”). ASU 2017-11 amends guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures. In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15, Presentation of Financial Statements—Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	12 Months Ended
	Jul. 31, 2017
Balance Sheet Related Disclosures [Abstract]
Schedule of Inventories	Inventories consist of the following: July 31, 2017 2016 Raw materials $ 82,000 $ 120,000 Finished goods 191,000 230,000 $ 273,000 $ 350,000
Schedule of Property Plant and Equipment	Property, plant, and equipment consist of the following: July 31, 2017 2016 Computers and equipment $ 1,045,000 $ 840,000 Furniture and fixtures 21,000 21,000 1,066,000 861,000 Less accumulated depreciation (518,000 ) (421,000 ) $ 548,000 $ 440,000
Schedule of Patents	Patents consist of the following: July 31, 2017 2016 Patents $ 3,485,000 $ 3,475,000 Less accumulated amortization (2,663,000 ) (2,495,000 ) $ 822,000 $ 980,000

Commitments And Contingencies (

Commitments And Contingencies (Tables)	12 Months Ended
	Jul. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum annual lease payments for our primary facility as of July 31, 2017 are as follows: 2018 $ 94,000 2019 $ 106,000 2020 $ 45,000 $ 245,000

Fair Value of Financial Instr22

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Jul. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Derivative Liabilities at Fair Value	The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the years ended July 31, 2017 and 2016: Fair Value of Significant Unobservable Inputs (Level 3) Warrant Liability Balance at July 31, 2015 $ 4,000 Issuances 9,867,000 Settlement of warrant liability (13,550,000 ) Adjustments to estimated fair value 5,481,000 Balance at July 31, 2016 $ 1,802,000 Issuances — Settlement of warrant liability (226,000 ) Adjustments to estimated fair value 277,000 Balance at July 31, 2017 $ 1,853,000

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jul. 31, 2017
Equity [Abstract]
Schedule of Warrant Activity	A summary of our warrant activity and related data is as follows: Shares Outstanding at July 31, 2015 5,035,156 Issued 20,376,219 Exercised (2,898,670 ) Expired (15,456,279 ) Outstanding at July 31, 2016 7,056,426 Issued 1,724,235 Exercised (347,451 ) Expired/Cancelled (129,374 ) Outstanding at July 31, 2017 8,303,836
Schedule of Warrants Outstanding	The following table summarizes information related to warrants outstanding at July 31, 2017: Expiration Exercise Date Price Shares 09/17/17 $ 1.38 113,520 01/24/18 $ 0.83 375,000 08/29/19 $ 0.75 4,104,980 11/23/20 $ 0.45 1,986,101 12/01/21 $ 1.25 1,176,472 12/01/21 $ 1.28 117,647 01/23/22 $ 1.25 396,469 01/23/22 $ 1.28 33,647 8,303,836

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Restricted Stock Activity	A summary of our restricted stock unit activity and related data is as follows: Shares Outstanding at July 31, 2015 3,210,000 Granted 1,272,500 Vested (2,075,000 ) Forfeited (1,122,500 ) Outstanding at July 31, 2016 1,285,000 Granted 1,150,000 Vested (150,000 ) Forfeited (250,000 ) Outstanding at July 31, 2017 2,035,000
Schedule of Stock Option Activity	A summary of our stock option activity for the fiscal years ended July 31, 2017 and 2016 is as follows: Shares Weighted- Average Exercise Price Aggregate Intrinsic Value Outstanding at July 31, 2015 434,218 $ 4.07 $ — Granted 1,850,000 $ 1.07 Exercised — $ — Cancelled (6,250 ) $ 2.20 Outstanding at July 31, 2016 2,277,968 $ 1.60 $ 46,000 Granted 3,735,000 $ 1.05 Exercised — $ — Cancelled (253,125 ) $ 1.42 Outstanding at July 31, 2017 5,759,843 $ 1.25 $ 1,120,000
Schedule of Fair Value Assumptions	The fair value of stock options was estimated at the grant date using the following weighted average assumptions: For the years ended July 31, 2017 2016 Volatility 81.00 % 82.12 % Risk-free interest rate 1.70 % 0.83 % Dividend yield 0.0 % 0.0 % Expected life 4.66 years 2.13 years

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Significant components of our deferred tax assets are as follows: July 31, 2017 2016 Net operating loss carry-forward $ 30,970,000 $ 30,160,000 Stock options and warrants 3,250,000 3,250,000 Other temporary differences (140,000 ) (140,000 ) Total deferred tax assets 34,080,000 33,270,000 Valuation allowance for deferred tax assets (34,080,000 ) (33,270,000 ) Net deferred tax assets $ — $ —
Schedule of Reconciliation Effective Tax Rate, Percentage	A reconciliation of income taxes computed using the statutory income tax rate, compared to the effective tax rate, is as follows: 2017 2016 Federal tax benefit at the expected statutory rate 34.0 % 34.0 % State income tax, net of federal tax benefit 0.8 1.9 Expired net operating loss carryforwards (6.6 ) (1.5 ) Other (7.7 ) — Change in state tax rates (4.2 ) — Permanent items (3.3 ) (17.9 ) Valuation allowance (13.0 ) (16.5 ) Income tax benefit - effective rate 0.0 % 0.0 %

Organization And Business (Deta

Organization And Business (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Cumulative net loss	$ 109,482,000	$ 103,219,000
Cash and cash equivalents	1,640,000	5,194,000	$ 1,321,000
Accounts payable	426,000	$ 479,000
Long term debt
2014 Private Placement [Member]
Number of warrants to purchase common stock	4,756,163
Proceeds from issuance of common stock	$ 2,800,000
2015 Private Placement [Member]
Number of warrants to purchase common stock	4,756,163
Proceeds from issuance of common stock	$ 2,800,000
2017 Private Placement [Member]
Number of warrants to purchase common stock	4,756,163
Proceeds from issuance of common stock	$ 2,800,000

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Accounting Policies [Abstract]
Restricted cash	$ 75,000	$ 75,000
Impairment expense		$ 48,000
Computation of basic net loss per common share	16,098,679	10,619,394
Allowance for doubtful accounts	$ 0	$ 0

Balance Sheet Details (Details

Balance Sheet Details (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Inventory wrote off	$ 50,000
Sale of inventory	34,000	46,000
Inventory finished goods net of reserves	34,000	46,000
Depreciation expense	98,000	40,000
Impairment expense		48,000
Patents [Member]
Amortization expense	$ 178,000	$ 179,000
Weighted average remaining amortization period for patents	5 years
Amortization expense, next twelve months	$ 178,000
Amortization expenses, year two	178,000
Amortization expenses, year three	178,000
Amortization expenses, year four	178,000
Amortization expenses, year five	$ 178,000

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Inventory (Details) - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 82,000	$ 120,000
Finished goods	191,000	230,000
Inventory, net	$ 273,000	$ 350,000

Balance Sheet Details - Sched30

Balance Sheet Details - Schedule of Property Plant and Equipment (Details) - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Computers and equipment	$ 1,045,000	$ 840,000
Furniture and fixtures	21,000	21,000
Property, plant and equipment, gross	1,066,000	861,000
Less accumulated depreciation	(518,000)	(421,000)
Property, plant and equipment, net	$ 548,000	$ 440,000

Balance Sheet Details - Sched31

Balance Sheet Details - Schedule of Patents (Details) - USD ($)	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Patents		$ 3,475,000	$ 3,485,000
Less accumulated amortization		(2,495,000)	(2,663,000)
Patents, net	$ 822,000	$ 980,000	$ 822,000

Commitments and Contingencies32

Commitments and Contingencies (Details Narrative) - USD ($)	Aug. 13, 2013	Jul. 31, 2017	Jul. 31, 2016
Restructuring liability		$ 19,000	$ 39,000
Rent expense		$ 116,000	$ 99,000
Dennis Brovarone [Member]
Release agreement payment	$ 91,000
Cash severance payment period	60 months
Monthly installment amount	$ 1,600

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)	Jul. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 94,000
2,019	106,000
2,020	45,000
Future minimum annual lease payments	$ 245,000

Fair Value of Financial Instr34

Fair Value of Financial Instruments - Schedule of Derivative Liabilities at Fair Value (Details) - Warrant Liability [Member] - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Beginning balance	$ 1,802,000	$ 4,000
Issuances		9,867,000
Settlement of warrant liabilities	(226,000)	(13,550,000)
Adjustments to estimated fair value	277,000	5,481,000
Ending balance	$ 1,853,000	$ 1,802,000

Derivative Liability (Details N

Derivative Liability (Details Narrative) - USD ($)	Nov. 23, 2015	Oct. 23, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2012
Proceeds from exercise of warrants			$ 185,000	$ 1,269,000
Derivative liabilities			$ 1,853,000	1,802,000
Warrants outstanding			8,303,836
Change in fair value of warrant liability			$ 277,000	$ 5,481,000
Bridge Loan [Member]
Warrants outstanding			9,709
Number of warrants exercise during the period			5,335
Issuance of share of common stock			4,179
Remaining warrants to be issued			4,374
November Closing Date [Member]
Proceeds from exercise of warrants			$ 106,000
Number of warrants to purchase common stock			236,116
2015 Private Placement Financing [Member]
Number of warrants issued			20,376,219
2015 Private Placement Financing [Member] | Six-Month Warrant [Member]
Number of warrants issued				2,820,670
2015 Private Placement Financing [Member] | October Closing Date [Member] | Five Years [Member]
Number of warrants to purchase common stock		6,666,666
Warrant term		5 years
2015 Private Placement Financing [Member] | October Closing Date [Member] | Six Months [Member]
Number of warrants to purchase common stock		8,666,666
Warrant term		6 months
2015 Private Placement Financing [Member] | November Closing Date [Member]
Number of warrants issued					132,420
Warrants liabilities			$ 1,853,000
Warrants outstanding			1,986,101
Stock price			$ 1.25
Warrant expiration warrant exercise price			$ 0.45
Fair value assumption of historical stock price volatility			70.00%
Fair value assumption of risk free interest rate			1.60%
Fair value assumption of warrant expiration term			3 years 3 months 19 days
2015 Private Placement Financing [Member] | November Closing Date [Member] | Six-Month Warrant [Member]
Number of warrants to purchase common stock	2,820,670
2015 Private Placement Financing [Member] | November Closing Date [Member] | Five Years [Member]
Number of warrants to purchase common stock	2,222,217
Warrant term	5 years
2015 Private Placement Financing [Member] | November Closing Date [Member] | Six Months [Member]
Warrant term	6 months
Private Placement Financing [Member] | Five Years [Member]
Warrant term				5 years
Private Placement Financing [Member] | Six Months [Member]
Warrant term				6 months
Private Placement Financing [Member] | October Closing Date [Member]
Derivative liabilities			$ 7,008,000
Proceeds from private placement			6,000,000
Other expenses			1,008,000
Private Placement Financing [Member] | November Closing Date [Member]
Proceeds from private placement			2,000,000
Other expenses			859,000
Private Placement Financing [Member] | October Closing Date1 [Member]
Derivative liabilities			$ 2,859,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Feb. 06, 2017	Jan. 23, 2017	Dec. 01, 2016	Apr. 13, 2016	Jul. 31, 2017	Jul. 31, 2016
Preferred stock shares authorized					5,000,000	5,000,000
Preferred stock shares par value					$ 0.01	$ 0.01
Common stock shares authorized					100,000,000	100,000,000
Common stock shares par value					$ 0.01	$ 0.01
Warrant exercise price
Proceeds from exercise of warrants					$ 185,000	$ 1,269,000
Value of shares issued for services						$ 290,000
Restricted Stock Units RSU [Member]
Aggregate number of shares					150,000	2,075,000
October Closing Date [Member] | Private Placement Financing [Member]
Proceeds from private placement					$ 6,000,000
November Closing Date [Member]
Number of warrants to purchase common stock					236,116
Proceeds from exercise of warrants					$ 106,000
November Closing Date [Member] | Private Placement Financing [Member]
Proceeds from private placement					$ 2,000,000
Warrant [Member]
Aggregate number of shares						41,178
Number of warrants to purchase common stock					342,116	2,820,670
Warrants issued					5,335
Proceeds from exercise of warrants					$ 185,000	$ 1,269,000
Number of warrants issued					4,179	78,000
Exercise of warrants derivative features					236,116
Exercise of warrants equity instruments					106,000
Private Placement Financing [Member]
Proceeds from private placement		$ 337,000			$ 1,049,000
Purchase price per share		$ 0.85
Number of warrants to purchase common stock		396,469
Maximum warrants to purchase common stock shares		396,469
Warrant exercise price		$ 1.25
Warrant term		5 years
Private Placement Financing [Member] | Placement Agent Warrant [Member]
Number of warrants to purchase common stock					151,294
Warrant exercise price					$ 1.275
Aggregate cash fees paid to placement agent					$ 128,600
Due diligence fees paid					12,000
Reimbursement of counsel fees					35,000
Private Placement Financing [Member] | Accredited Investors [Member]
Proceeds from private placement			$ 1,000,000
Purchase price per share			$ 0.85
Number of warrants to purchase common stock			1,176,472
Maximum warrants to purchase common stock shares			1,176,472
Warrant exercise price			$ 1.25
Warrant term			5 years
Private Placement Offering [Member]
Aggregate number of shares	1,572,941
Private Placement Offering [Member] | Maximum [Member]
Aggregate number of shares value	$ 1,572,941
2015 Private Placement Financing [Member]
Investment affiliates					472,000
2015 Private Placement Financing [Member] | October Closing Date [Member]
Proceeds from private placement					$ 6,000,000
Aggregate number of shares					13,333,333
2015 Private Placement Financing [Member] | November Closing Date [Member]
Proceeds from private placement					$ 2,000,000
Aggregate number of shares					4,444,439
2015 Private Placement Financing [Member] | Warrant One [Member] | October Closing Date [Member]
Number of warrants to purchase common stock					6,666,666
Warrant term					5 years
2015 Private Placement Financing [Member] | Warrant One [Member] | November Closing Date [Member]
Number of warrants to purchase common stock					2,222,217
Warrant term					5 years
2015 Private Placement Financing [Member] | Warrant Two [Member] | October Closing Date [Member]
Number of warrants to purchase common stock					8,666,666
Warrant term					6 months
2015 Private Placement Financing [Member] | Warrant Two [Member] | November Closing Date [Member]
Number of warrants to purchase common stock					2,820,670
Warrant term					6 months
Six Months [Member] | Private Placement Financing [Member]
Warrant term						6 months
Warrants issued						2,820,670
Five Years [Member] | Private Placement Financing [Member]
Warrant term						5 years
Services Agreement [Member]
Aggregate number of shares						250,000
Aggregate number of shares value						$ 290,000
Value of shares issued for services					$ 144,000	43,000
Services Agreement 1 [Member]
Value of shares issued for services						$ 182,000
Service Agreement [Member]
Number of common shares issued for services				250,000
Value of shares issued for services				$ 290,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrant Activity (Details) - shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Equity [Abstract]
Warrants outstanding begining balance	7,056,426	5,035,156
Warrants issued	1,724,235	20,376,219
Warrant exercised	(347,451)	(2,898,670)
Warrants expired	(129,374)	(15,456,279)
Warrant outstanding ending balance	8,303,836	7,056,426

Stockholders' Equity - Schedu38

Stockholders' Equity - Schedule of Warrants Outstanding (Details)	Jul. 31, 2017$ / sharesshares
Warrants outstanding | shares	8,303,836
Warrant exercise price per share | $ / shares
09/17/17 [Member]
Warrants outstanding | shares	113,520
Warrant exercise price per share | $ / shares	$ 1.38
01/24/18 [Member]
Warrants outstanding | shares	375,000
Warrant exercise price per share | $ / shares	$ 0.83
08/29/19 [Member]
Warrants outstanding | shares	4,104,980
Warrant exercise price per share | $ / shares	$ 0.75
11/23/20 [Member]
Warrants outstanding | shares	1,986,101
Warrant exercise price per share | $ / shares	$ 0.45
12/01/21 [Member]
Warrants outstanding | shares	1,176,472
Warrant exercise price per share | $ / shares	$ 1.25
12/01/21 [Member]
Warrants outstanding | shares	117,647
Warrant exercise price per share | $ / shares	$ 1.28
01/23/22 [Member]
Warrants outstanding | shares	396,469
Warrant exercise price per share | $ / shares	$ 1.25
01/23/22 [Member]
Warrants outstanding | shares	33,647
Warrant exercise price per share | $ / shares	$ 1.28

Share-Based Compensation (Detai

Share-Based Compensation (Details Narrative) - USD ($)	Jan. 31, 2017	Dec. 13, 2016	Oct. 31, 2016	Jul. 31, 2016	Feb. 29, 2016	Jul. 31, 2017	Jul. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						3,735,000	1,850,000
2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares increase under the plan					4,000,000
Share-based compensation, expiration date					Feb. 4, 2026
Contractual life vesting periods					10 years
Number of shares available for issuance under the plan						561,000
Stock Option Plans [Member] | Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						600,000	850,000
Option awards vesting percentage							100.00%
Contractual life vesting periods						5 years	1 year
RSU Cancellation Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-vest expense reversed						$ 87,000
Henry R. Lambert [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock							200,000
Option awards vesting percentage				33.00%
Contractual life vesting periods							5 years
Pfanzelter [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						200,000	200,000
Option awards vesting percentage			33.00%
Contractual life vesting periods						5 years	5 years
Officers and Directors [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						2,950,000	950,000
Officers and Directors [Member] | RSU Cancellation Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of vested shares of common stock		3,900,000
Henry R. Lambert Option Award [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						200,000
Contractual life vesting periods						5 years
Mark S. Elliott [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						150,000	150,000
Contractual life vesting periods						5 years	2 years
Messrs. Cohee, Lee, Otis and Dr. Theno [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						100,000	100,000
Option awards vesting percentage	34.00%
Contractual life vesting periods						5 years	5 years
Scientific Advisory Board Member [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						100,000
Contractual life vesting periods						5 years
Third Party Consultants [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						85,000	50,000
Aggregate number of vested shares of common stock							12,500
Contractual life vesting periods						5 years
Restricted Stock Units RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, share-based compensation						150,000	2,075,000
Options issued to purchase common stock
Aggregate number of vested shares of common stock						150,000	2,075,000
Restricted stock units outstanding						2,035,000
Shares expected to vest						1,150,000
Unrecognized non-cash compensation costs						$ 1,302,000
Unrecognized non-cash compensation costs, weighted average period						3 years 3 months 26 days
Share based compensation granted stock						1,150,000	1,272,500
Share-based compensation						$ 102,000	$ 1,544,000
Restricted Stock Units RSU [Member] | Officers and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, share-based compensation						1,150,000
December 31 2018 Member] | Henry R. Lambert [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						200,000
Option awards vesting percentage						25.00%
December 31 2018 Member] | Pfanzelter [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						500,000
Option awards vesting percentage						25.00%
December 31 2018 Member] | Henry R. Lambert Option Award One [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						400,000
Option awards vesting percentage						25.00%
Contractual life vesting periods						10 years
December 31 2018 Member] | Pfanzelter One [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						1,000,000
Option awards vesting percentage						25.00%
Contractual life vesting periods						10 years
January 15 2018 [Member] | Messrs. Cohee, Lee and Otis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						150,000
Option awards vesting percentage						50.00%
January 15 2018 [Member] | Messrs. Cohee, Lee and Otis [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock						200,000
Option awards vesting percentage						50.00%
Contractual life vesting periods						10 years
January 15 2019 [Member] | Messrs. Cohee, Lee and Otis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards vesting percentage						50.00%
January 15 2019 [Member] | Messrs. Cohee, Lee and Otis [Member] | Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards vesting percentage						50.00%
Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation						$ 968,000	$ 358,000
Weighted-average contractual term of options outstanding						5 years 7 months 28 days
Stock options were exercisable						2,729,843
Exercise price						$ 1.43
Aggregate intrinsic value						$ 654,000
Weighted average contractual term						3 years 2 months 16 days
Weighted average grant date fair value for options granted						$ 0.67	$ 0.47
Unrecognized compensation cost of unvested stock option grants						$ 1,892,000
Weighted-average contractual term of expected to vest						3 years 18 days

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Restricted Stock Activity (Details) - Restricted Stock Units RSU [Member] - shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Outstanding, Shares, Beginning Balance	1,285,000	3,210,000
Granted	1,150,000	1,272,500
Vested	(150,000)	(2,075,000)
Forfeited	(250,000)	(1,122,500)
Outstanding, Shares, Ending Balance	2,035,000	1,285,000

Share-Based Compensation - Sc41

Share-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding Shares, Beginning Balance	2,277,968	434,218
Options Granted, Shares	3,735,000	1,850,000
Option Exercised, Shares
Options Cancelled, Shares	(253,125)	(6,250)
Options Outstanding Shares, Ending Balance	5,759,843	2,277,968
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 1.60	$ 4.07
Weighted Average Exercise Price Granted	1.05	1.07
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Cancelled	1.42	2.20
Weighted Average Exercise Price Outstanding, Ending Balance	$ 1.25	$ 1.60
Aggregate Intrinsic Value Outstanding, Beginning Balance	$ 46,000
Aggregate Intrinsic Value Outstanding, Ending Balance	$ 1,120,000	$ 46,000

Share-Based Compensation - Sc42

Share-Based Compensation - Schedule of Fair Value Assumptions (Details)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Volatility	81.00%	82.12%
Risk-free interest rate	1.70%	0.83%
Dividend yield	0.00%	0.00%
Expected life	4 years 7 months 28 days	2 years 1 month 16 days

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Net product sales	$ 1,831,000	$ 1,289,000
Accounts receivables	297,000	263,000
SDC Technology [Member]
Accounts receivables	6,000	24,000
Due to related parties	75,000	118,000
ICC [Member]
Net product sales	$ 33,000	$ 34,000

Sales Concentration (Details Na

Sales Concentration (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Sales revenue	$ 1,831,000	$ 1,289,000
Sales Revenue, Net [Member] | U.S [Member]
Concentration risk percentage	100.00%	100.00%
Sales Revenue, Net [Member] | Two Individual Customer [Member]
Concentration risk percentage	33.00%	19.00%
Sales Revenue, Net [Member] | Other Individual Customer [Member]
Concentration risk percentage	10.00%	10.00%
Sales Revenue, Net [Member] | One Customer [Member]
Concentration risk percentage	37.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Provision for income tax	$ 1,600	$ 1,600
Federal operating loss carry forwards	100,300,000	95,400,000
State operating loss carry forward	74,700,000	79,000,000
Operating loss carry forward	$ 18,600,000
Ownership change percentage	50.00%
Federal operating loss carry forwards expiration date	Jul. 31, 2037
State operating loss carry forwards expiration date	Jul. 31, 2037
Valuation allowance deferred tax asset change in amount	$ 810,000	2,423,000
Accrued interest or penalties

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Net operating loss carry-forward	$ 30,970,000	$ 3,016,000
Stock options and warrants	3,250,000	3,250,000
Other temporary differences	(140,000)	(140,000)
Total deferred tax assets	34,080,000	33,270,000
Valuation allowance for deferred tax assets	(34,080,000)	(33,270,000)
Net deferred tax assets

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation Effective Tax Rate Percentage (Details)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Federal tax benefit at the expected statutory rate	34.00%	34.00%
State income tax, net of federal tax benefit	0.80%	1.90%
Expired net operating loss carryforwards	(0.066)	(0.015)
Other	(7.70%)
Change in state tax rates	(4.20%)
Permanent items	(3.30%)	(17.90%)
Valuation allowance	(13.00%)	(16.50%)
Income tax benefit - effective rate	0.00%	0.00%

Subsequent Events (Details Nara

Subsequent Events (Details Narative) - USD ($)	Sep. 25, 2017	Jul. 31, 2017	Aug. 25, 2017
Outstanding number of warrants to purchase common shares		8,303,836
Subsequent Event [Member] | Two Thousand Fourteen Warrant [Member]
Number of warrants to purchase common stock	1,491,649	2,533,331	4,104,980
Shares issued price per share		$ 0.75
Subsequent Event [Member] | Two Thousand Fourteen Warrant [Member] | Maximum [Member]
Shares issued price per share			$ 0.75
Subsequent Event [Member] | Two Thousand Fourteen Warrant [Member] | Minimum [Member]
Shares issued price per share			$ 0.60
Subsequent Event [Member] | 2015 Warrant [Member]
Number of warrants to purchase common stock			1,986,101
Subsequent Event [Member] | 2015 Warrant [Member] | Maximum [Member]
Shares issued price per share			$ 0.45
Subsequent Event [Member] | 2015 Warrant [Member] | Minimum [Member]
Shares issued price per share			$ 0.40
Subsequent Event [Member] | 2017 Warrant [Member]
Number of warrants to purchase common stock	1,396,470	176,471	1,572,941
Shares issued price per share		$ 1.25
Proceeds from issuance of common shares	$ 2,720,000
Subsequent Event [Member] | 2017 Warrant [Member] | Maximum [Member]
Shares issued price per share			$ 1.25
Subsequent Event [Member] | 2017 Warrant [Member] | Minimum [Member]
Shares issued price per share			$ 0.85
Subsequent Event [Member] | 2015 Warrant [Member]
Number of warrants to purchase common stock	1,599,135	268,909
Proceeds from issuance of common shares		$ 107,000
Subsequent Event [Member] | 2015 Warrant [Member] | Garden State Securities Inc [Member]
Number of warrants to purchase common stock		4,756,163
Proceeds from issuance of common shares		$ 2,830,000